Does the TCN2 rs1801198 CG genotype impair cellular vitamin B12 delivery and raise homocysteine despite normal serum B12?

The TCN2 rs1801198 polymorphism represents a significant genetic factor in vitamin B12 metabolism, particularly regarding how B12 is delivered to cells versus how it appears in standard blood tests.

Clinical and effectiveness evidence

Research indicates that the rs1801198 G allele (Pro259Arg) is associated with reduced concentrations of holotranscobalamin (holo-TC), the "active" form of B12 that tissues can actually use.

• Holo-TC reduction: Individuals with the CG or GG genotypes consistently show lower levels of holo-TC compared to those with the CC genotype. This is critical because holo-TC represents only about 10–30% of total serum B12, yet it is the only fraction available for cellular uptake.
• Homocysteine elevation: Meta-analyses have confirmed that the GG genotype is associated with higher homocysteine levels (standardized mean difference: 0.070, p=0.01).
• Discordance with serum markers: Because total serum B12 tests measure both active (holo-TC) and inactive (haptocorrin-bound) B12, individuals with the rs1801198 variant may present with "normal" serum B12 levels while experiencing functional intracellular deficiency. This is often validated by elevations in methylmalonic acid (MMA), a more sensitive functional marker of B12 status.

Mechanistic explanations

The TCN2 gene encodes transcobalamin II, the transport protein essential for carrying B12 into cells via receptor-mediated endocytosis.

• Protein Stability: The substitution of proline for arginine at position 259 is thought to alter the structural stability or binding affinity of the transcobalamin protein.
• Cellular Uptake: Reduced efficiency in this transport system limits the amount of B12 reaching the interior of cells, where it serves as a necessary cofactor for the enzyme methionine synthase.
• Metabolic Stall: In the absence of sufficient intracellular B12, methionine synthase cannot efficiently convert homocysteine to methionine. This "stalls" the remethylation pathway, leading to a backup and subsequent rise of homocysteine in the blood.

Bottom line

The TCN2 rs1801198 CG genotype reduces cellular B12 delivery by impairing transcobalamin efficiency. This can lead to elevated homocysteine levels and functional B12 deficiency even when standard serum B12 markers and dietary intake appear adequate. For individuals with this variant, measuring holotranscobalamin and methylmalonic acid (MMA) provides a more accurate assessment of B12 status than total serum B12 alone.